A weight-loss drug called Contrave may be approved by the Food and Drug Administration in the coming weeks if the agency follows the advice of one of its panels, which recently weighed in on the ...

WASHINGTON (AP) — U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation’s 78 million obese ...

LOS ANGELES (WABC) -- Controlling cravings and suppressing hunger have been big challenges for people trying to lose weight, and now, a prescription pill called Contrave claims it can help with both ...

Contrave is a combination therapy consisting of naltrexone, an opioid antagonist, and bupropion, an aminoketone antidepressant. Results showed no statistically significant difference in the incidence ...

On Tuesday, the LaJolla, Calif.-based developer of a drug it calls Contrave tries to succeed where at least three other pharmaceutical firms have failed in recent years -- to win over a panel of ...

San Diego’s Orexigen Therapeutics, maker of a weight-loss drug that had once promised to improve the treatment of obesity, has agreed to sell its assets for $75 million cash. The buyer is Nalpropion ...

LOS ANGELES (KABC) -- Controlling cravings and suppressing hunger have been big challenges for people trying to lose weight. A prescription weight loss pill called Contrave claims it can help with ...

SAN DIEGO, Dec. 11, 2013 -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the Company has resubmitted the Contrave® New Drug Application to the United States (U.S.) Food and Drug ...

Orexigen Therapeutics Inc. said Tuesday that U.S. health officials declined to approve the experimental weight loss pill Contrave and want the company to conduct an additional study to address ...

Orexigen announced that it has resubmitted a New Drug Application (NDA) to the FDA for Contrave (naltrexone sustained release [SR]/bupropion SR), an investigational drug for weight loss and ...

SAN DIEGO, Oct. 1, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Kwang Dong Pharmaceutical Company, Ltd., has filed a New Drug Application with the Ministry of ...

Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceutical Company Limited (Takeda) (TSE:4502) announced today that the United States Food and Drug Administration (FDA) has issued a ...